Market closed
Ocugen, Inc/$OCGN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ocugen, Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ticker
$OCGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
65
Website
Ocugen, Inc Metrics
BasicAdvanced
$224M
Market cap
-
P/E ratio
-$0.20
EPS
3.77
Beta
-
Dividend rate
Price and volume
Market cap
$224M
Beta
3.77
52-week high
$2.11
52-week low
$0.37
Average daily volume
4.5M
Financial strength
Current ratio
2.58
Quick ratio
2.455
Long term debt to equity
12.282
Total debt to equity
16.695
Management effectiveness
Return on assets (TTM)
-47.98%
Return on equity (TTM)
-103.30%
Valuation
Price to revenue (TTM)
42.871
Price to book
5.49
Price to tangible book (TTM)
5.49
Price to free cash flow (TTM)
-4.097
Growth
Revenue change (TTM)
-33.94%
Earnings per share change (TTM)
-41.83%
3-year earnings per share growth (CAGR)
-8.56%
What the Analysts think about Ocugen, Inc
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ocugen, Inc stock.
Ocugen, Inc Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Ocugen, Inc Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Ocugen, Inc News
AllArticlesVideos
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewsWire·2 days ago
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
GlobeNewsWire·1 week ago
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ocugen, Inc stock?
Ocugen, Inc (OCGN) has a market cap of $224M as of December 21, 2024.
What is the P/E ratio for Ocugen, Inc stock?
The price to earnings (P/E) ratio for Ocugen, Inc (OCGN) stock is 0 as of December 21, 2024.
Does Ocugen, Inc stock pay dividends?
No, Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Ocugen, Inc dividend payment date?
Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocugen, Inc?
Ocugen, Inc (OCGN) has a beta rating of 3.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.